Headline: Jakarta’s KPU Clarifies New Nomenklatur: Pramono Anung–Rano Karno Now Gubernur and Wakil Gubernur of DKJ, Not DKI
The Jakarta branch of the Election Commission (KPU) has officially released a statement clarifying the new nomenclature for the recently elected governor and vice governor of the Special Capital Region of Jakarta (DKJ). The announcement comes following the latest revision of the Special Capital Region of Jakarta (UU DKJ) passed on November 12, 2024.
KPU Jakarta’s Chairperson, Wahyu Dinata, confirmed the change, "Following the recent revision of UU DKJ, we are now using DKJ instead of DKI in our nomenclature. This includes our references to the governor, vice governor, and the provincial legislature."
The revision of the law, as per Article 70A, has changed the nomenclature for several regional institutions, including the governor and vice governor positions, from DKI to DKJ. With this new classification, the KPU has officially declared Pramono Anung and Rano Karno as the elected governor and vice governor of DKJ.
The KPU’s decision was outlined in their official decree, KPU Jakarta Nomor 9 Tahun 2025, which states that Jakarta is no longer considered the capital city but rather the Special Capital Region of Jakarta (DKJ). The decree also reveals that the winning pair, Pramono Anung and Rano Karno, secured 50.07% of the total valid votes, amounting to 2,183,239 votes.
- Anak Krakatau Eruption: Satellite & Monitoring Data
- Russia and Ukraine Agree to Halt Energy Strikes
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)